Intravenous infusion of up to 20 mg of BPC-157 in 2 healthy adults showed no adverse effects and was well-tolerated. Lee & Burgess, Alternative Therapies in Health and Medicine, 2025 Limitations : Only 2 participants Very short observation period No long-term follow-up No efficacy endpoints What These Studies Tell UsAnd What They Dont What We Can Reasonably Conclude Short-term tolerance appears acceptable : Across all three studies (roughly 30 participants total), no adverse events were reported
Dosage varies based on body weight, severity, route of administration, and veterinary recommendations
View GHK-Cu (Copper Peptide) If you're on hormone replacement therapy, birth control, or fertility treatments, let your FormBlends provider know
How BPC-157 Compares to Other Peptides When you compare BPC-157 to other peptides, the most glaring difference is the lack of robust human data
After a median of 12.75 months, treatment with Enhertu led to an overall response rate of 37.1%, while duration of response was 11.3 months
